Key result
Metoprolol treatment in chronic heart failure patients with depression, anxiety, and burn-out was associated with a significant improvement in quality of life at 12 months (P < .05).
Why the study?
Psychological disorders like depression and anxiety are associated with chronic heart failure, motivating an evaluation of mental status effects on quality of life in metoprolol-treated patients with depression, anxiety, and burn-out.
Does metoprolol treatment improve quality of life in chronic heart failure patients with depression, anxiety, and burn-out?
Cohort (n=154)
No
Does metoprolol treatment improve quality of life in chronic heart failure patients with depression, anxiety, and burn-out?
p-value: p=<.05
Metoprolol treatment is associated with significant long-term improvements in quality of life among chronic heart failure patients with comorbid depression, anxiety, and burnout.
Should not yet change practice; leaves open need for RCTs to confirm association in HF with psychiatric comorbidities.
Psychological disorders, such as depression and anxiety, are known to be associated with chronic heart failure (CHF). The present study was conducted to evaluate the effect of mental status on quality of life (QoL) in metoprolol treated CHF patients with depression, anxiety, and burn-out.This single-center prospective study was conducted between February 2013 and April 2016, enrolled CHF patients (resting heart rate >80 bpm) with depression, anxiety, and burn out at baseline. Hospital anxiety and depression scale (HADS) and Copenhagen burnout inventory (CBI) were used to assess the depression-anxiety status and burn-out status, respectively. Change in QoL was evaluated as the endpoint at 1st, 3rd, 6th, and 12th month from baseline using Minnesota Living with Heart Failure Questionnaire (MLHFQ) and short form-8 (SF-8) scales. A student t test was used to determine the change and P value < .05 was considered statistically significant. One hundred fifty-four patients were enrolled (median age 66 years; 65.58% males) and divided into 8 groups based on the HADS and CBI scores at baseline. Overall, the mean SF8 score and MLHFQ scores in different mental status groups showed a significant improvement (P < .05) in QoL from baseline to 12th month, with no significant difference reported between the groups. With regard to the follow-up periods, there was a deterioration in QoL until 3rd month, after which there was a significant improvement (P < .05).There was a significant improvement in QoL in metoprolol treated CHF patients with depression, anxiety, and burn-out.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) conducted a cohort in Chronic heart failure with depression, anxiety, and burn-out (n=154). Metoprolol was evaluated on Change in quality of life (QoL) from baseline to 12 months using MLHFQ and SF-8 scales (p=<.05). Metoprolol treatment in chronic heart failure patients with depression, anxiety, and burn-out was associated with a significant improvement in quality of life at 12 months (P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: